The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Research Report 2024
Synopsis
SCID (severe combined immunodeficiency) is a group of rare disorders which occurs by mutations in genes involved in the development and function of infection-fighting immune cells. A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). To help confirm the diagnosis, additional blood tests, including a total blood cell count, may be ordered.SCID (X-linked severe combined immunodeficiency) is an inherited immune system illness that affects virtually exclusively men. Because they lack the required immune cells to fight off some bacteria, viruses, and fungi, boys with X-linked SCID are prone to recurring and persistent illnesses.
Global Severe Combined Immunodeficiency (SCID) Diagnosis market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Severe Combined Immunodeficiency (SCID) Diagnosis market research.
The global severe combined immunodeficiency (SCID) diagnosis market refers to the market for diagnostic tests used to identify and diagnose infants with SCID, a rare genetic disorder that affects the immune system. SCID is characterized by a severe deficiency in both T cells and B cells, which are crucial for the body’s immune response. Infants with SCID are highly susceptible to severe infections and require early diagnosis and treatment.
The market for SCID diagnosis includes various laboratory-based tests and screening programs. Laboratory-based tests typically involve analyzing blood samples to assess the presence and function of immune cells. Commonly used tests include flow cytometry, T-cell receptor excision circle (TREC) analysis, and next-generation sequencing (NGS) methods to detect gene mutations associated with SCID. Additionally, newborn screening programs using dried blood spot samples have also been implemented in some regions to identify infants with SCID early on.
The global SCID diagnosis market is driven by several factors. One of the primary drivers is the increasing awareness and understanding of SCID among healthcare professionals and the general population. As a result, more infants are being tested for SCID, leading to earlier detection and prompt treatment initiation. Additionally, advancements in genetic testing technologies, such as NGS, have improved the accuracy and efficiency of SCID diagnosis.
Furthermore, government initiatives and newborn screening programs in various countries have contributed to the growth of the SCID diagnosis market. These programs aim to identify infants with SCID shortly after birth, allowing for early intervention and improved outcomes. For example, the implementation of SCID newborn screening programs in several U.S. states has significantly increased the detection of affected infants and facilitated early treatment.
Geographically, North America currently dominates the global SCID diagnosis market. This is primarily due to the higher prevalence of SCID in certain populations, well-established healthcare infrastructure, and the implementation of newborn screening programs. Europe is also a significant market, while other regions, such as Asia-Pacific and Latin America, are expected to witness growth as awareness and healthcare infrastructure continue to improve.
Key players in the global SCID diagnosis market include diagnostic laboratories, healthcare providers, and companies specializing in genetic testing. These companies focus on developing innovative testing methods, improving existing diagnostic tools, and collaborating with healthcare professionals and researchers to advance SCID diagnosis and management.
Overall, the global SCID diagnosis market is expected to witness substantial growth in the coming years, driven by factors such as increased awareness, advancements in genetic testing technologies, and the implementation of newborn screening programs. Early diagnosis and timely intervention are crucial for improving outcomes and quality of life for infants with SCID, emphasizing the importance of continued efforts in SCID diagnosis and management.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Severe Combined Immunodeficiency (SCID) Diagnosis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
ARCHIMEDlife
PerkinElmer
Health Research, Inc
Winfertility
Portea Medical
LaCAR MDX Technologies
Labsystems Diagnostics Oy
Devyser Diagnostics
Revcovi
Leadiant Biosciences
Segment by Type
TREC Test
Complete Blood Count (CBC)
Genetic Test
Biochemical Test
Others
Segment by Application
Hospital
Outpatient Center
Diagnostic and Research Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Severe Combined Immunodeficiency (SCID) Diagnosis report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
SCID (severe combined immunodeficiency) is a group of rare disorders which occurs by mutations in genes involved in the development and function of infection-fighting immune cells. A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). To help confirm the diagnosis, additional blood tests, including a total blood cell count, may be ordered.SCID (X-linked severe combined immunodeficiency) is an inherited immune system illness that affects virtually exclusively men. Because they lack the required immune cells to fight off some bacteria, viruses, and fungi, boys with X-linked SCID are prone to recurring and persistent illnesses.
Global Severe Combined Immunodeficiency (SCID) Diagnosis market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Severe Combined Immunodeficiency (SCID) Diagnosis market research.
The global severe combined immunodeficiency (SCID) diagnosis market refers to the market for diagnostic tests used to identify and diagnose infants with SCID, a rare genetic disorder that affects the immune system. SCID is characterized by a severe deficiency in both T cells and B cells, which are crucial for the body’s immune response. Infants with SCID are highly susceptible to severe infections and require early diagnosis and treatment.
The market for SCID diagnosis includes various laboratory-based tests and screening programs. Laboratory-based tests typically involve analyzing blood samples to assess the presence and function of immune cells. Commonly used tests include flow cytometry, T-cell receptor excision circle (TREC) analysis, and next-generation sequencing (NGS) methods to detect gene mutations associated with SCID. Additionally, newborn screening programs using dried blood spot samples have also been implemented in some regions to identify infants with SCID early on.
The global SCID diagnosis market is driven by several factors. One of the primary drivers is the increasing awareness and understanding of SCID among healthcare professionals and the general population. As a result, more infants are being tested for SCID, leading to earlier detection and prompt treatment initiation. Additionally, advancements in genetic testing technologies, such as NGS, have improved the accuracy and efficiency of SCID diagnosis.
Furthermore, government initiatives and newborn screening programs in various countries have contributed to the growth of the SCID diagnosis market. These programs aim to identify infants with SCID shortly after birth, allowing for early intervention and improved outcomes. For example, the implementation of SCID newborn screening programs in several U.S. states has significantly increased the detection of affected infants and facilitated early treatment.
Geographically, North America currently dominates the global SCID diagnosis market. This is primarily due to the higher prevalence of SCID in certain populations, well-established healthcare infrastructure, and the implementation of newborn screening programs. Europe is also a significant market, while other regions, such as Asia-Pacific and Latin America, are expected to witness growth as awareness and healthcare infrastructure continue to improve.
Key players in the global SCID diagnosis market include diagnostic laboratories, healthcare providers, and companies specializing in genetic testing. These companies focus on developing innovative testing methods, improving existing diagnostic tools, and collaborating with healthcare professionals and researchers to advance SCID diagnosis and management.
Overall, the global SCID diagnosis market is expected to witness substantial growth in the coming years, driven by factors such as increased awareness, advancements in genetic testing technologies, and the implementation of newborn screening programs. Early diagnosis and timely intervention are crucial for improving outcomes and quality of life for infants with SCID, emphasizing the importance of continued efforts in SCID diagnosis and management.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Severe Combined Immunodeficiency (SCID) Diagnosis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
ARCHIMEDlife
PerkinElmer
Health Research, Inc
Winfertility
Portea Medical
LaCAR MDX Technologies
Labsystems Diagnostics Oy
Devyser Diagnostics
Revcovi
Leadiant Biosciences
Segment by Type
TREC Test
Complete Blood Count (CBC)
Genetic Test
Biochemical Test
Others
Segment by Application
Hospital
Outpatient Center
Diagnostic and Research Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Severe Combined Immunodeficiency (SCID) Diagnosis report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 TREC Test
1.2.3 Complete Blood Count (CBC)
1.2.4 Genetic Test
1.2.5 Biochemical Test
1.2.6 Others
1.3 Market by Application
1.3.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Outpatient Center
1.3.4 Diagnostic and Research Laboratories
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Perspective (2018-2029)
2.2 Severe Combined Immunodeficiency (SCID) Diagnosis Growth Trends by Region
2.2.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Severe Combined Immunodeficiency (SCID) Diagnosis Historic Market Size by Region (2018-2023)
2.2.3 Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Region (2024-2029)
2.3 Severe Combined Immunodeficiency (SCID) Diagnosis Market Dynamics
2.3.1 Severe Combined Immunodeficiency (SCID) Diagnosis Industry Trends
2.3.2 Severe Combined Immunodeficiency (SCID) Diagnosis Market Drivers
2.3.3 Severe Combined Immunodeficiency (SCID) Diagnosis Market Challenges
2.3.4 Severe Combined Immunodeficiency (SCID) Diagnosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Severe Combined Immunodeficiency (SCID) Diagnosis Players by Revenue
3.1.1 Global Top Severe Combined Immunodeficiency (SCID) Diagnosis Players by Revenue (2018-2023)
3.1.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue Market Share by Players (2018-2023)
3.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Severe Combined Immunodeficiency (SCID) Diagnosis Revenue
3.4 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Concentration Ratio
3.4.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Severe Combined Immunodeficiency (SCID) Diagnosis Revenue in 2022
3.5 Severe Combined Immunodeficiency (SCID) Diagnosis Key Players Head office and Area Served
3.6 Key Players Severe Combined Immunodeficiency (SCID) Diagnosis Product Solution and Service
3.7 Date of Enter into Severe Combined Immunodeficiency (SCID) Diagnosis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Severe Combined Immunodeficiency (SCID) Diagnosis Breakdown Data by Type
4.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Historic Market Size by Type (2018-2023)
4.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Type (2024-2029)
5 Severe Combined Immunodeficiency (SCID) Diagnosis Breakdown Data by Application
5.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Historic Market Size by Application (2018-2023)
5.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2018-2029)
6.2 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2018-2023)
6.4 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2018-2029)
7.2 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2018-2023)
7.4 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2018-2029)
8.2 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2018-2023)
8.4 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2018-2029)
9.2 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2018-2023)
9.4 Latin America Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2018-2029)
10.2 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2018-2023)
10.4 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ARCHIMEDlife
11.1.1 ARCHIMEDlife Company Detail
11.1.2 ARCHIMEDlife Business Overview
11.1.3 ARCHIMEDlife Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.1.4 ARCHIMEDlife Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.1.5 ARCHIMEDlife Recent Development
11.2 PerkinElmer
11.2.1 PerkinElmer Company Detail
11.2.2 PerkinElmer Business Overview
11.2.3 PerkinElmer Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.2.4 PerkinElmer Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.2.5 PerkinElmer Recent Development
11.3 Health Research, Inc
11.3.1 Health Research, Inc Company Detail
11.3.2 Health Research, Inc Business Overview
11.3.3 Health Research, Inc Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.3.4 Health Research, Inc Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.3.5 Health Research, Inc Recent Development
11.4 Winfertility
11.4.1 Winfertility Company Detail
11.4.2 Winfertility Business Overview
11.4.3 Winfertility Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.4.4 Winfertility Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.4.5 Winfertility Recent Development
11.5 Portea Medical
11.5.1 Portea Medical Company Detail
11.5.2 Portea Medical Business Overview
11.5.3 Portea Medical Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.5.4 Portea Medical Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.5.5 Portea Medical Recent Development
11.6 LaCAR MDX Technologies
11.6.1 LaCAR MDX Technologies Company Detail
11.6.2 LaCAR MDX Technologies Business Overview
11.6.3 LaCAR MDX Technologies Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.6.4 LaCAR MDX Technologies Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.6.5 LaCAR MDX Technologies Recent Development
11.7 Labsystems Diagnostics Oy
11.7.1 Labsystems Diagnostics Oy Company Detail
11.7.2 Labsystems Diagnostics Oy Business Overview
11.7.3 Labsystems Diagnostics Oy Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.7.4 Labsystems Diagnostics Oy Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.7.5 Labsystems Diagnostics Oy Recent Development
11.8 Devyser Diagnostics
11.8.1 Devyser Diagnostics Company Detail
11.8.2 Devyser Diagnostics Business Overview
11.8.3 Devyser Diagnostics Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.8.4 Devyser Diagnostics Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.8.5 Devyser Diagnostics Recent Development
11.9 Revcovi
11.9.1 Revcovi Company Detail
11.9.2 Revcovi Business Overview
11.9.3 Revcovi Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.9.4 Revcovi Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.9.5 Revcovi Recent Development
11.10 Leadiant Biosciences
11.10.1 Leadiant Biosciences Company Detail
11.10.2 Leadiant Biosciences Business Overview
11.10.3 Leadiant Biosciences Severe Combined Immunodeficiency (SCID) Diagnosis Introduction
11.10.4 Leadiant Biosciences Revenue in Severe Combined Immunodeficiency (SCID) Diagnosis Business (2018-2023)
11.10.5 Leadiant Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
